|Description||GW 441756 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor (IC50 = 2 nM), reducing cell proliferation and potentiates the effects of chemotherapeutic agents.|
|Solubility||Soluble in DMSO|
|Storage||Store at -20 °C|
|Application||A specific Tropomyosin-related kinase A (TrkA) inhibitor|
|Quality Standard||Enterprise Standard|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
NTR 368 is a peptide fragment corresponding to residues 368-381 of the human p75 neurotrophin receptor (p75NTR).
This active molecular is a selective pan-TRK inhibitor. GNE-8525 shows potent antiproliferation activity (IC50 = 0.003 μM) and it shows in vivo antitumor effica...
The sulfate salt form of LOXO-101, also called Larotrectinib, is a ATP-competitive inhibitor of tropomyosin receptor kinases and is still under Phase II clinica...
Tavilermide is a selective, small-molecule partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.
TPX-0005 is an orally available and potent ATP-competitive inhibitor of ALK/ROS1/TRK (IC50= 5.3 nM for SRC, IC50= 1.01 nM, 1.26 nM and 1.08 nM for mutant ALKs i...
AZ 23 is a potent and selective tyrosine kinase (Trk) inhibitor with the potential for therapeutic utility in neuroblastoma and multiple other cancer indication...
GW 441756 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor (IC50 = 2 nM), reducing cell proliferation and potentiates the effects of chem...
Cyclotraxin B is a selective and potent Trk B (BDNF/NT-3) receptor inhibitor with an IC50 value of 0.30 nM. It prevents receptor activation by BDNF without inte...
PF 06273340 is a potent and selective, orally bioavailable pan-Trk kinase inhibitor with IC50 of 6, 2, and 1 nM for Trk A, B and C, respectively. PF 06273340 is...
Belizatinib is inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases (TRK). Belizatinib can bind to and inhibit both ALK and TRK ki...
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, which activates hippocampal and striatal TrkB and TrkC, and their downstream signaling, and increas...
Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Phase 2.
ANA-12 is a selective TrkB antagonist. ANA-12 showed direct and selective binding to TrkB and inhibited processes downstream of TrkB without altering TrkA and T...